Kornimate/medical-research-clean huggingface dataset:
role of 12-lipoxygenase in platelet reactivity and type 2 diabetes mellitus

Conditions: Thrombosis; Type 2 Diabetes Mellitus

Summary: this study investigates the potential protective effects of fatty acid supplementation through inhibition of platelet activation. fatty acids (omega-3 and omega-6) will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls. post-menopausal women with type 2 diabetes mellitus and healthy post-menopausal women will be treated with omega-3 and omega-6 fatty acid supplements to determine protection from platelet activation and thrombosis in this high risk population.

essential fatty acids such as omega-3 and omega-6 have been shown to play important roles in regulating platelet activation, but the underlying mechanisms have not been fully elucidated as well as their true protection from thrombosis. 12-lipoxygenase oxidized fatty acids are known to play both a pro- and anti-thrombotic effect on platelets depending on the fatty acid. oxidation of arachidonic acid by 12-lipoxygenase resuts in a pro-thrombotic bioactive lipid whereas oxidation of the omega-6 fatty acid dgla found in plant oil results in formation of a potent anti-thrombotic bioactive lipid. determining the extent of protection from this and other bioactive lipids produced through oxygenase activity will allow for a better understanding of which fatty acid supplementation may best protect from thrombosis. essential fatty acids such as omega-3 (dha/epa) and omega-6 (dgla) appear to be protective. however the underlying mechanism for this potential protection is not well understood. identifying the mechanism by which these supplements protect from platelet activation may identify new approaches to preventing thrombotic events in this high risk population.

Eligibility criteria:
inclusion criteria: * healthy subjects and t2dm patients * postmenopausal women with t2dm * all races and ethnicities * t2dm patients taking 1st line diabetic treatment (i.e. metformin) exclusion criteria: * fish and plant oil supplements 2 months prior to enrollment * nsaids and aspirin 1 week prior to enrollment * cardiovascular event within 6 months prior to enrollment * other anti-platelet treatment including pde and p2y12 inhibitors

Keywords: platelets 12-lipoxygenase fatty acids dgla dha epa 12-lox
prevalence of lower urinary tract symptoms in women with gynecologic malignancy planning to undergo surgical management

Conditions: Lower Urinary Tract Symptoms; Gynecologic Malignancy

Summary: this study is to determine the prevalence of lower urinary tract symptoms in women undergoing surgery for gynecologic malignancy.

lower urinary tract symptoms, including urinary incontinence, voiding dysfunction, urgency, frequency, fecal incontinence, as well as sexual dysfunction, is directly affected by gynecologic malignancies and the surgical and medical management of those malignancies. increased risk of injury to the urinary tract is a recognized complication of surgical and medical therapy of gynecologic malignancies. to date, only a few studies have looked at the incidence of lower urinary tract symptoms at the time of diagnosis of gynecologic malignancy and prior to treatment, and there have been no published studies describing the incidence of sexual dysfunction at the time of diagnosis and prior to therapy of gynecologic malignancies. however, sexual dysfunction has been described in patients with urinary incontinence and pelvic organ prolapse and following surgery for incontinence and pelvic organ prolapse.

Eligibility criteria:
inclusion criteria: * subjects with a new diagnosis of gynecologic malignancy who plan to undergo surgical management, including cervical, endometrial, and ovarian cancer. exclusion criteria: * subjects less than 18 years of age * subjects unable to give informed consent

Keywords: lower urinary tract symptoms gynecologic malignancy urinary incontinence fecal incontinence frequency voiding dysfunction sexual dysfunction
study will evaluate the safety and efficacy of anidulafungin in patients with candidemia or invasive candidiasis

Conditions: Candidiasis

Summary: the purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or tissue. currently the drug is approved for treatment using a daily dose of iv medication until 14 days after the fungus disappears from the blood. this study will evaluate the effectiveness of intravenous anidulafungin when it is administered for 5-28 days followed by oral antifungal medication. study patients will be assessed for response to treatment throughout the study drug treatment period.


Eligibility criteria:
inclusion criteria: * male or female subjects \> or equal to 18 years of age. * presence of candidemia (positive blood culture) or invasive candidiasis (histopathologic or cytopathologic examination of a needle aspiration or biopsy specimen from a normally sterile site excluding mucous membranes showing yeast cells) obtained within the prior 96 hours of the screening visit. * subjects who received no more than one prior dose of an echinocandin or polyene. exclusion criteria: * subjects with hypersensitivity to anidulafungin, other echinocandins or azoles. * presence of confirmed or suspected candida osteomyelitis, endocarditis or meningitis. * subjects with infected prosthetic devices which cannot be removed within 24 hours

Keywords: candidemia invasive candidiasis fungal bloodstream infection
effect of resveratrol and vitamin c on insulin resistance among postmenopausal women

Conditions: Postmenopausal; Insulin Resistance

Summary: hormonal and metabolic changes because of postmenopause increase body weight, central abdominal fat, alter lipid profile and insulin resistance, those factors increase the risk up to 60% to develop metabolic syndrome, diabetes and cardiovascular diseases. because there is no efficient antioxidant therapy in postmenopausal women, this study proposes a therapy with resveratrol and vitamin c to increase the total antioxidant capacity; as well as to decrease insulin resistance and in consequence decreased the risk of diabetes, metabolic syndrome and cardiovascular disease

currently, there are not studies that demonstrate an efficient antioxidant therapy in postmenopausal women, to increase the total antioxidant capacity and to decrease insulin resistance and biochemical parameters of cardio-metabolic risk. therefore, the aim of this study is to evaluate the effect of the co-administration of resveratrol and vitamin c on insulin resistance and antioxidant capacity by a double-blind randomized clinical trial. a population of 270 postmenopausal women will be studied, stratified into 3 groups: group 1: three-month administration of vitamin c 500 mg daily + placebo group 2: three-month administration of resveratrol 500 mg daily + placebo group 3: three months administration of vitamin c 500 mg daily and resveratrol 500 mg daily as antioxidant therapy. all participants will be monitored monthly for a period of 3 months: glucose, insulin, uric acid, homeostatic model assessment (homa), total cholesterol (tc), triglycerides (tgc), high density lipoproteins-cholesterol (hdl- c), low density lipoproteins-cholesterol (ldl), blood pressure, body mass index (bmi). the antioxidant efficiency in erythrocytes by the quantification of antioxidant enzymes (superoxide dismutase, catalase, glutathione reductase and glutathione peroxidase), as well as total antioxidant capacity in plasma. in order to corroborate the oxidative damage, the product of the lipoperoxidation malondialdehyde and the carbonylation of proteins will be evaluated by spectrophotometric techniques before and three months after the intervention.

Eligibility criteria:
inclusion criteria: * women diagnosed with early postmenopause according to straw classification. * insulin resistance determinated by homa ≥ 2.5. * not use of metformin, bezafibrates and / or statins, three months before enter to the study * no indication of hormone replacement therapy. * sign the informed consent. exclusion criteria: * women who present pathologies such as: diabetes mellitus, rheumatoid arthritis, lupus, neoplasms of any type, hiv, or kidney disease during the course of the study. * women who during the development of the protocol require hormone replacement therapy. * any type of surgical intervention during the following of the study. * that the patient wishes to withdraw from the study. * that the patient does not complete with 80% of adherence to the treatment

Keywords: resveratrol, vitamin c, antioxidant therapy, antioxidant capacity
koning breast computed tomography guided neoadjuvant treatment monitoring

Conditions: Breast Cancer

Summary: the hypothesis of this study is that using koning breast ct during the neoadjuvant treatment of breast cancer will allow for accurate tumor localization and tumor volume measurement, leading to improved surgical and radiation therapy outcomes.


Eligibility criteria:
inclusion criteria: * female gender * age 18 years or older * any ethnicity * are undergoing neoadjuvant therapy for locally advanced breast cancer with either chemotherapy or hormonal therapy * is able to provide informed consent. exclusion criteria: * pregnancy * lactation * women who are unable or unwilling to understand or to provide informed consent * women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker. * women who are unable to tolerate study constraints. * women who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to): * treatment for enlarged thymus gland as an infant * irradiation for benign breast conditions, including breast inflammation after giving birth * treatment for hodgkin's disease * women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram. * women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to): * tuberculosis * severe scoliosis

Keywords: breast ct
diagnosis of variceal bleeding and its control in cirrhosis

Conditions: Cirrhosis

Summary: the aim of the study was to determine the independent predictors of variceal bleeding and control of bleeding in cirrhosis as no scientific assessment have been perfomed until now


Eligibility criteria:
inclusion criteria: * cirrhotic patients admitted for an acute complication of cirrhosis * admission ≤ 6 hours of inclusion exclusion criteria: * child-pugh score \> 13 * digestive hemorrhage * non cirrhotic portal hypertension
clinical study of hernia ring closure method in laparoscopic abdominal wall hernia repair

Conditions: Abdominal Wall Hernia

Summary: by comparing the time of closing the hernia ring, the degree of pain, and the recovery of gastrointestinal tract in different groups intervening, infection, recurrence and medical cost, to find out whether patients with abdominal wall hernia have different hernias it is the best way to close the hernia ring under laparoscopy and provide evidence based medicine. with in the research process of the research group, a database on abdominal wall hernia will be established for the future further study of hernia has laid a solid foundation.


Eligibility criteria:
inclusion criteria: * conform to the diagnostic criteria of abdominal wall hernia; * patients with general physical condition and can tolerate general anesthesia and laparoscopic surgery; ③ after explaining the situation to the patients and their families, they agreed to join the research group. exclusion criteria: * the diagnostic criteria of abdominal wall hernia were not met; ② patients who have serious medical diseases and cannot tolerate laparoscopic surgery; ③ patients with mental illness; ④ the judgment is affected by incomplete data.
metabolic effects of androgenicity in aging men and women

Conditions: Aging; Insulin Resistance

Summary: the goal of this research study is to study the effect of testosterone or estrogen on blood sugar control and fat metabolism. changes in hormone levels with age may affect risk factors for heart disease such as diabetes. diabetes is a glandular condition associated with lack of the hormone insulin or an insensitivity to it resulting in problems with blood sugar control and fat metabolism. the effect of commonly used hormonal supplements such as testosterone by older adults on insulin and body composition is not well understood. in this study, the role of testosterone and estrogen on your ability to control blood sugar and your body composition will be assessed. the investigators plan to study 60 subjects. all of these subjects will be healthy older men between the ages of 60-85 years old who are not on testosterone therapy. subjects that are screened who have any clinically significant abnormalities detected on their screening physical exam or laboratory testing (e.g. prostate specific antigen \> 4), who have a history of prostate cancer, polycythemia, or who cannot take testosterone will not be included. if a subject is eligible to participate after initial screening, that subject will take medications to adjust their hormone levels and have tests performed that measure insulin sensitivity and adiposity before and after these hormone medications. the outcomes that will be measured are: 1) insulin sensitivity, 2) hormone levels (total and free testosterone levels, sex hormone-binding globulin levels) and 3) body composition and abdominal adiposity.


Eligibility criteria:
inclusion criteria: * males age 60-85 years * non-diabetic fasting glucose and 2-hour oral glucose tolerance test (ogtt) * overall good general medical health and signed informed consent * willing to travel to west los angeles va and university of california, los angeles in los angeles, california exclusion criteria: * any clinically significant abnormalities detected on screening physical exam or laboratory testing (e.g. prostate specific antigen \> 4) * or other symptom or history of a significant underlying medical or psychiatric illness * bmi \ 40 * subjects already on testosterone therapy or medications that might influence glucose regulation or hormone levels * subjects with a history of deep venous thromboses, pulmonary embolism, breast cancer, prostate cancer, polycythemia or other contraindications to estrogen or testosterone

Keywords: aging hormones insulin resistance
safety and efficacy of oral pf-4136309 in patients with chronic hepatitis c infection and abnormal liver enzymes

Conditions: Hepatitis C, Chronic

Summary: this study will evaluate the effect of pf-04136309 in patients with chronic hepatitic c virus infection and abnormal liver enzymes.

study recruitment was stopped on dec 15, 2011 due to difficulty in enrolling the targeted number of patients. subjects currently enrolled into the study will complete the study as per protocol. there were no safety concerns involved in the decision to stop enrollment. the new anticipated last subject last visit (lslv) is february 2012.

Eligibility criteria:
inclusion criteria: * chronic hcv infection * alt \>1.5 but \<10 times upper limit of normal exclusion criteria: * decompensated or severe liver disease defined by one or more of the following criteria: prior liver biopsy showing cirrhosis. * international normalized ratio (inr) greater than or equal to 1.5. * total bilirubin greater than or equal to 1.5x uln, or \>2x uln for unconjugated bilirubin. * serum albumin below normal. * alt or aspartate aminotransferase (ast) \>10 x uln. * evidence of portal hypertension including splenomegaly, ascites, encephalopathy, and/or esophageal varices. * presence of human immunodeficiency virus (hiv). * co-infection with hepatitis b virus (hbv). * co-infection with epstein barr virus (ebv) and/or cytomegalovirus (cmv).

Keywords: chronic hcv infection raised alt transaminitis hcv infection
investigator initiated trial to evaluate efficacy and safety of laennec (human placenta hydrolysate) administered by ultrasonography guided subacromial bursa injection in patients with shoulder impingement syndrome

Conditions: Shoulder Impingement Syndrome

Summary: to patients with shoulder collision syndrome, laennec (human placenta hydrolysate) is administered as an injection in the ultrasonic induction underglone, to evaluate the effectiveness and safety.


Eligibility criteria:
inclusion criteria: 1. at the time of screening, 19 or 70 years 2. those who are suspected of rotator cuff lesions or damage due to shoulder pain 3. those who are judged to have a shoulder joint disease during screening 4. neer test, hawkins-kennedy inspection, job test, painful arc inspection or resisted showder external rotation test 5. those with a significant pain of 30 mm of visual analogue scale (vas) 6. those who can sign a test subject or to comply with the matters required for clinical trials. exclusion criteria: 1. a person who appears in the movement of two or more shoulder joints with more than 50% of the joint movement limit on the passive shoulder joint operation scope test. 2. those who have confirmed the rupture of the entire layer by ultrasound 3. those with serious damage to the shoulders and the past power 4. those who have suspected fractures, dislocations, degenerative arthritis, and calcification in the shoulder radiation test in the shoulder radiation test. 5. those who complain of shoulder pain due to stroke, spinal cord injury, and other surgery 6. those with other shoulder diseases other than fifty dogs (rheumatoid arthritis, osteoarthritis, bone defect injuries, malignant tumors, etc.) 7. those who are accompanied by diseases of cervical spine or other upper limbs that have a significant effect on the shoulder 8. those who have performed steroid injections in the joint steel within 3 months of participation in clinical trials 9. those who have administered anti -inflammatory drugs within two weeks of participation in clinical trials 10. those with all other joint diseases that have musculoskeletal diseases that may affect effective evaluation, or that it is impossible to participate in this clinical trial. 11. those who are diagnosed with mental illness and taking drugs 12. pregnant women and lactation departments, fertility women who are not willing to contraceptive during the clinical trial period 13. those who have received medication, oriental medicine, physical therapy, and injection treatment in relation to shoulder pain within the last two weeks 14 those who are participating in other clinical trials during screening 15. those who determine that other testors are inadequate
memory and emotion in acute and chronic phases of cerebrovascular accident

Conditions: Cerebrovascular Accident

Summary: the purpose is to determine the relationship between anxiety and cognitive performances in patients with acute and chronic phases of cerebrovascular accident (cva). data from neuropsychological assessment concerning cognitive processes (working and episodic memory) sensitive to different dimensions of anxiety will be analyzed. the secondary purpose is to evaluate how some neurological (hemispherical lateralization of lesions), psychological (depression) and demographic (quality of life) variables can increase the effects of different dimensions of anxiety on cognitive processes, during the acute and/or chronic phase of cva.

data will be collected during usual neuropsychological evaluation and cerebral imagery examination (nihss, rankin scale) of patients in acute (0-1 month) and chronic (6 months) phases of cva.

Eligibility criteria:
inclusion criteria: * acute phase of carotid, vertebrobasilar or lacunar cerebrovascular accident with ischemic or hemorrhagic origin * right-handed * possible cooperation: understanding of french instructions * normal or corrected vision * normal or corrected hearing * mini-mental state examination score higher than pathologic threshold according to age and sociocultural level of patient * possible follow up of patient exclusion criteria: * hearing problems * vision problems * right hemiplegia or acute monoparesis of right upper limb * hemispatial neglect * apraxia * psychiatric or neurological history possibly interfering with neuropsychological evaluation * important defect of working memory or executive functions
study of venous thromboembolism risk profiles and prophylaxis in neurosurgical inpatients

Conditions: Venous Thromboembolism

Summary: venous thromboembolism (vte), comprising deep venous thrombosis (dvt), pulmonary embolism (pe), or both, is a life-threatening complication in postoperative patients. vte has been estimated an incidence ranged from 79 per 100000 to 269 per 100000 population1. the incidence of vte rises up to 3.0% in average among all postoperative neurosurgical patients in recent studies, but the number varies in a large range according to primary diseases. this cross-sectional study was aimed to investigate the incidence, associated risk factors, prophylaxis, treatment, and outcomes of vte in a large clinical neurosurgery center in china.

venous thromboembolism (vte), comprising deep venous thrombosis (dvt), pulmonary embolism (pe), or both, is a life-threatening complication in postoperative patients. this cross-sectional study was aimed to investigate the incidence, associated risk factors, prophylaxis, treatment, and outcomes of vte in a large clinical neurosurgery center in china. 9010 patients underwent neurosurgery procedure were included. distribution of age, sex, whether received picc during perioperative period, and some special primary diseases are significantly different between vte and non-vte patients. student's test and chi-square test were performed for analyses. we investigated vte incidence, risk factors, prophylaxes, treatment and outcomes in postoperative neurosurgical patients, and summarized the vte susceptible population of the patients, providing a vte patient profile for neurosurgeons to concern.

Eligibility criteria:
inclusion criteria: neurosurgical inpatients. underwent neurosurgery procedure. exclusion criteria: acute or chronic respiratory failure. acute myocardial infarction or other serious heart diseases.

Keywords: venous thromboembolism deep venous thrombosis neurosurgery pulmonary embolism